Correspondence 0001193125-23-233859 from UroGen Pharma Ltd. (URGN) (CIK 0001668243) (URGN)
UroGen Pharma Ltd. (URGN) (CIK 0001668243)
Date: Sept. 13, 2023 · CIK: 0001668243 · Accession: 0001193125-23-233859
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-274423
Letter
UroGen Pharma Ltd.
400 Alexander Park Drive, 4th Floor
Princeton, New Jersey 08540
VIA EDGAR
September 13, 2023
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Tamika N. Sheppard
Re:
UroGen Pharma Ltd.
Registration Statement on Form S-3
File No. 333-274423
Acceleration Request
Requested Date:
Friday, September 15, 2023
Requested Time:
4:00 p.m. Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, UroGen Pharma Ltd. hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-274423) (the “Registration Statement”) to become effective on September 15, 2023, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable.
Once the Registration Statement has been declared effective, please orally confirm that event with Charles J. Bair of Cooley LLP at (858) 550-6142 or Asa M. Henin of Cooley LLP at (858) 550-6104. Thank you for your assistance with this matter.
Sincerely,
UROGEN PHARMA LTD.
Show Raw Text
CORRESP 1 filename1.htm CORRESP UroGen Pharma Ltd. 400 Alexander Park Drive, 4th Floor Princeton, New Jersey 08540 VIA EDGAR September 13, 2023 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Tamika N. Sheppard Re: UroGen Pharma Ltd. Registration Statement on Form S-3 File No. 333-274423 Acceleration Request Requested Date: Friday, September 15, 2023 Requested Time: 4:00 p.m. Eastern Time Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, UroGen Pharma Ltd. hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-274423) (the “Registration Statement”) to become effective on September 15, 2023, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable. Once the Registration Statement has been declared effective, please orally confirm that event with Charles J. Bair of Cooley LLP at (858) 550-6142 or Asa M. Henin of Cooley LLP at (858) 550-6104. Thank you for your assistance with this matter. Sincerely, UROGEN PHARMA LTD. By: /s/ Don Kim Don Kim Chief Financial Officer